About Pharmacology and Drug Discovery
Conference Mind Official Announcement - Welcome to the best reviewed Global Conference Community:
Team Conference Mind welcomes you all around the globe to be a part of “Global Webinar on Pharmacology and Drug Discovery” slotted on September 22-23, 2021.
Theme: Current Research & Future of Drug Development
“Global Pharmacology 2021” Conference includes Keynote talk, Plenary talks, Symposiums, Workshops, Poster Presentation and Panel discussion on the advanced research developments in the field of Pharmacology and Drug Discovery.
Pharmacology is the study of the body's reaction to drugs; it is the science of what is happening to your body and to the drug itself. The role of pharmacology is to understand why these changes are happening, allowing us to develop better drugs. Pharmacology integrates the knowledge of many disciplines, including
- Veterinary medicine.
Pharmacology is a separate discipline in the health sciences.
Track 2: Drug Discovery and Development:
Drug discovery and development together are the complete process of identifying a new drug and bringing it to market. Discovery may involve screening of chemical libraries, identification of the active ingredient from a natural remedy or design resulting from an understanding of the target. Development includes studies on microorganisms and animals, cli
Tracks and Key Topics
- Track 2 : Drug Discovery and Development
- Track 4 : Preclinical Research
- Track 3 : Drug Metabolism
- Track 1 : Pharmacology
- Track 5 : Pharmacokinetics
- Track 6 : Structure-Based Drug Design
- Track 7 : Artificial Intelligence
- Track 8 : Novel Antibiotics
- Track 9 : Proteomics
- Track 10 : Clinical Pharmacology
- Track 11 : Drug Tolerance
Organizing Committee Member
The global pharmaceuticals market was worth $934.8 billion in 2017 and will reach $1170 billion in 2021, growing at 5.8%, according to a recent pharma market research report by The Business Research Company.
This is an accelerated pace compared to 5.2% for the years before 2017, but is slower than the other two large healthcare segments, medical equipment and healthcare services. Healthcare as a whole is growing at over 7% year on year. Part of the explanation for the relatively slow current growth of the pharma market is that the launch of major new products has slowed and that companies are restricting their R&D investment. For example, despite the huge potential for any effective and safe new drug for treating Alzheimer’s disease, Pfizer has ended its Alzheimer’s research program while AstraZeneca and GSK have cut back. High failure rates, the $2 billion average cost of developing a new drug, and falling returns on investment — down from 10.1% a year in 2010 to 3.2% in 2017 for the big pharma companies, according to Deloitte’s — are restraining the launch of high-priced new breakthrough drugs such as those that boosted the market in earlier years.